cellular immune responses to nine mycobacterium tuberculosis vaccine candidates following intranasal vaccination到九结核分枝杆菌疫苗的细胞免疫应答方面候选人后鼻内接种疫苗.pdfVIP

Cellular Immune Responses to Nine Mycobacterium tuberculosis Vaccine Candidates following Intranasal Vaccination 1 1 1 2 3 Suraj B. Sable *, Mani Cheruvu , Subhadra Nandakumar , Sunita Sharma , Kakali Bandyopadhyay , 3 1 1 2 1 Kathryn L. Kellar , James E. Posey , Bonnie B. Plikaytis , Rama Rao Amara , Thomas M. Shinnick 1 Division of TB Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America, 2 Department of Microbiology and Immunology, Emory Vaccine Center and Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, United States of America, 3 Biotechnology Core Facility Branch, Division of Scientific Resources, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America Abstract Background: The identification of Mycobacterium tuberculosis vaccines that elicit a protective immune response in the lungs is important for the development of an effective vaccine against tuberculosis. Methods and Principal Findings: In this study, a comparison of intranasal (i.n.) and subcutaneous (s.c.) vaccination with the BCG vaccine demonstrated that a single moderate dose delivered intranasally induced a stronger and sustained M. tuberculosis-specific T-cell response in lung parenchyma and cervical lymph nodes of BALB/c mice than vaccine delivered subcutaneously. Both BCG and a multicomponent subunit vaccine composed of ni